AstraZeneca PLC CEO in London Trial Will Take Stand Over Seroquel Diabetes Risk

Published: Jun 20, 2008

Delaware Online -- The chief executive of AstraZeneca PLC is set to be deposed today regarding allegations the company hid the risk that its anti-psychotic drug Seroquel could cause diabetes in users.

David Brennan, who led AstraZeneca's U.S. unit in Fairfax before being appointed CEO of the London-based drug maker in 2006, will answer questions in London from attorneys representing thousands of plaintiffs across the Unites States.

Back to news